StrongTrack Record BioPier has a proven history of on-time delivery with a perfect quality track record across late-phase studies, including rescuing six pivotal Phase-3 trials between 2019 and 2022. This positions them as a reliable partner for sponsors facing at-risk programs and tight deadlines.

RareDisease Focus With over 150 studies since 2015 spanning Rare Diseases, Oncology, GI, CNS, Vaccines, and more, BioPier demonstrates breadth and depth in high-need therapeutic areas, suggesting opportunities for sponsors seeking specialized biostatistics and programming support in complex clinical programs.

USBasedReliability Operating 100% in the USA with an experienced, US-based team, BioPier can be a compelling option for sponsors requiring domestic CRO support, faster regulatory alignment, and alignment with FDA expectations for sNDA/sBLA submissions.

CompetitivePricing A project-based and unit-based model with flat, slim reporting structures keeps costs low and vendors lean, which may appeal to sponsors looking for cost-efficient collaboration on ongoing studies and submission activities.

CapacityGrowth Small to mid-size team (11-50 employees) with low turnover and senior staff directly managing projects suggests capacity for scalable support, potential upsell into expanded services such as ISS, ISE, HTA, FDA-IR, and CDISC migrations for ongoing or new submissions.